The approval and launch of new medicines/biological products for marketing often means the availability of new treatment for patients and advancement in health care.
Read more at: http://www.mondaq.com/india/x/784030/Healthcare/USFDA+records+highest+number+of+Novel+Drug+approvals+in+2018
The trend of continued rejection of compulsory license applications in India goes against the local generic drug manufacturers and public health safeguards incorporated in the Indian patent law.
Read more : : https://www.epw.in/journal/2019/5/commentary/compulsory-licensing-pharmaceutical.html
Shifting focus from generic drugs to specialty drugs amidst continued price erosion in the USA, Indian.
Read more : https://www.thepharmaletter.com/article/indian-drugmakers-urged-to-tap-cancer-market-and-innovation
Indian pharma industry, worth $34 billion in 2018, has exhibited huge potential and is expected to grow at a compound annual growth rate (CAGR) of 15 per cent.
Read more : https://www.theweek.in/news/biz-tech/2019/02/18/Indian-pharma-players-need-to-explore-new-regions-for-exports.html
The latest set of clinical trial rules, likely to be notified in March, will fast-track proposal clearances for Indian companies rather than their multinational counterparts.
Read more : https://www.thehindubusinessline.com/news/new-rules-sweeten-the-deal-for-clinical-trials-by-indian-pharma-cos/article26283499.ece